问题 › 团队未执行计划 › HealthTech & Digital Health
当好计划没有被执行时，通常原因是组织理性地优化了风险收入份额和客户留存。 数字健康公司面临特定困境——结果风险的签署速度快于公司判断自身能否承担的速度，12个月测量窗口对11个月销售周期。在此定价前，风险收入份额会持续变动且无人能归因，关于决策延迟的争论仍停留在意见层面。
当好计划没有被执行时，通常原因是组织理性地优化了风险收入份额和客户留存。 数字健康公司面临特定困境——结果风险的签署速度快于公司判断自身能否承担的速度，12个月测量窗口对11个月销售周期。在此定价前，风险收入份额会持续变动且无人能归因，关于决策延迟的争论仍停留在意见层面。
执行失败很少是因为不愿执行。通常是计划要求的行为与风险收入份额、参与率或毛利率所鼓励的方向冲突，人们按结构支付的方式解决了这一冲突。
诊断问题不是“为什么没人做这件事”，而是“被要求放弃什么，谁为此补偿”。要求团队牺牲自身归因结果或PMPM去成全他人结果的计划不会运行，无论沟通得多好。
第二个常见原因是算术问题：计划所需产能超出在册成员总量，组织不说出来，而是悄悄做能做的部分，其余部分从未发生。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 风险份额和参与目标已理解并同意，但数字每周仍持平。
✓ 进展报告的是新签署的客户或PMPM预订，而不是已交付的归因结果。
✓ 被要求改变的团队，其考核指标是毛利率或客户流失，而改变会推高这些指标。
通常会让情况更糟的做法。 更努力地沟通，这针对的是不存在的理解问题，并拖延了发现与风险收入份额挂钩的激励问题。
It is for you if you run or finance a digital health company and the plan is understood and agreed and still nothing changes. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Convert 2.9M contracted lives into Medicare Advantage outcomes contracts using existing payer integrations and outcomes proof points.
The leak it closes. Prevents value leakage to in-house payer solutions by demonstrating superior 12-month cohort outcomes data
The assumption it rests on. At least 4 of 34 existing health plans will sign MA outcomes contracts within 24 months — the engine put the probability at 0.75.
| Investment required | $1.8-2.4M total over 24 months |
| Expected return | 250-580% over 36 months on $62M base revenue |
| Revenue, year 1 | $2-4M incremental ARR (2-3 MA contracts) |
| Revenue, year 2 | $6-14M incremental ARR (4-7 MA contracts) |
| Revenue, year 3 | $12-25M incremental ARR (8-12 MA contracts) |
| Exit criteria | Abandon if fewer than 2 MA contracts signed by month 18 OR if engagement rate in MA pilot cohort falls below 30% OR if NCQA certification denied |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 组织对齐模型, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
在要求人们改变行为前，先改变他们的考核指标。支持更可靠地跟随激励，而非跟随解释。
偶尔是。更常见的是结构问题伪装成人问题，先测试结构值得，因为替换人员无法修复结构，且发现成本高昂。
通常是的，但出于产能而非理解原因。三个符合可用产能的优先事项，胜过十二个不符合的优先事项。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית